Effect of vitamin D supplementation on total and allergen-specific IgE in children with asthma and low vitamin D levels - 05/01/22
Abstract |
Background |
Observational studies have yielded inconsistent findings for the relation between vitamin D level and total IgE or allergic sensitization.
Objective |
To determine whether vitamin D supplementation reduces levels of total IgE and IgE to each of 2 common indoor allergens in children with asthma and low vitamin D levels.
Methods |
Total IgE, IgE to Dermatophagoides pteronyssinus, and IgE to Blattella germanica were measured at the randomization and exit visits for 174 participants in the Vitamin D Kids Asthma Study, a multicenter, double-blind, randomized placebo-controlled trial of vitamin D3 supplementation (4000 IU/d) to prevent severe exacerbations in children with persistent asthma and vitamin D levels less than 30 ng/mL. Multivariable linear regression was used for the analysis of the effect of vitamin D supplementation on change in each IgE measure.
Results |
Participants were followed for an average of 316 days. At the exit visit, more subjects in the vitamin D arm achieved a vitamin D level equal to or more than 30 ng/mL compared with those in the placebo arm (87% vs 30%; P < .001). In a multivariable analysis, vitamin D3 supplementation had no significant effect on change in total IgE, IgE to Dermatophagoides pteronyssinus, or IgE to Blattella germanica between the exit and randomization visits (eg, for log10 total IgE, β = 0.007; 95% CI, −0.061 to 0.074; P = .85).
Conclusions |
Vitamin D supplementation, compared with placebo, has no significant effect on serum levels of total IgE, IgE to dust mite, or IgE to cockroach in children with asthma and low vitamin D levels.
Le texte complet de cet article est disponible en PDF.Key words : Vitamin D, asthma, immunoglobulin E, children
Abbreviations used : Bla g, Der p
Plan
| This study was funded by the US National Institutes of Health (NIH; grant no. HL119952). The project was also supported by the Pediatric Clinical and Translational Research Center at the University of Pittsburgh Medical Center Children’s Hospital of Pittsburgh through the NIH (grant no. UL1TR001857). F.J.R.’s contribution was supported by the NIH (grant no. KL2 TR001856). Pharmavite LLC provided the vitamin D and placebo capsules for the study, and Glaxo Smith Kline provided the Flovent given to study participants. |
|
| Disclosure of potential conflict of interest: W. Phipatanakul has served as consultant for Glaxo Smith Kline (GSK), Genentech, Novartis, Regeneron, Sanofi, and Teva; has received clinical trial support or medications from Genentech, Novartis, Regeneron, Sanofia, Circassia, Monaghen, Thermo Fisher, Alk Abello, Lincoln Diagnostics, GSK, Kaleo, and Merck; and reports funding to the institution by Genentech, Regeneron, Novartis, and the US National Institutes of Health (NIH), all for projects unrelated to the current work. T. W. Guilbert reports personal fees from the American Board of Pediatrics (Pediatric Pulmonary Subboard), GSK, and Teva; grants from Astra-Zeneca and Novartis; grants and personal fees from Sanofi/Regeneron; and other support from UpToDate, all unrelated to the current work. M. D. Cabana is a member of the United States Preventive Services Task Force (USPSTF). J. C. Celedón has received Asmanex from Merck for another NIH-funded study, unrelated to the current work. The contents of this study do not necessarily represent the views of the USPSTF. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 149 - N° 1
P. 440 - janvier 2022 Retour au numéro
Article précédent
- Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS
- Caspar I. van der Made, Judith Potjewijd, Annemiek Hoogstins, Huub P.J. Willems, Arjan J. Kwakernaak, Ruud G.L. de Sevaux, Paul L.A. van Daele, Annet Simons, Marloes Heijstek, David B. Beck, Mihai G. Netea, Pieter van Paassen, A. Elizabeth Hak, Lars T. van der Veken, Marielle E. van Gijn, Alexander Hoischen, Frank L. van de Veerdonk, Helen L. Leavis, Abraham Rutgers
- Distinct immune trajectories in patients with chromosome 22q11.2 deletion syndrome and immune-mediated diseases
- T. Blaine Crowley, Ian M. Campbell, Emily J. Liebling, Michele P. Lambert, Lorraine E. Levitt Katz, Jennifer Heimall, Alice Bailey, Daniel E. McGinn, Donna M. McDonald McGinn, Kathleen E. Sullivan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?